CA3027969A1 - Compositions and methods of treating dry eye syndrome and other traumatized non-keratinized epithelial surfaces - Google Patents

Compositions and methods of treating dry eye syndrome and other traumatized non-keratinized epithelial surfaces Download PDF

Info

Publication number
CA3027969A1
CA3027969A1 CA3027969A CA3027969A CA3027969A1 CA 3027969 A1 CA3027969 A1 CA 3027969A1 CA 3027969 A CA3027969 A CA 3027969A CA 3027969 A CA3027969 A CA 3027969A CA 3027969 A1 CA3027969 A1 CA 3027969A1
Authority
CA
Canada
Prior art keywords
composition
chitosan
serum
freeze
polymer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3027969A
Other languages
English (en)
French (fr)
Inventor
Matthew B. Dowling
Steven E. Lazar
Helga M. Gentile
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eye Care International LLC
Original Assignee
Eye Care International LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eye Care International LLC filed Critical Eye Care International LLC
Publication of CA3027969A1 publication Critical patent/CA3027969A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A61B5/4869—Determining body composition
    • A61B5/4875—Hydration status, fluid retention of the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/722—Chitin, chitosan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/51—Umbilical cord; Umbilical cord blood; Umbilical stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Developmental Biology & Embryology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medical Informatics (AREA)
  • Surgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Reproductive Health (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
CA3027969A 2016-06-16 2017-06-16 Compositions and methods of treating dry eye syndrome and other traumatized non-keratinized epithelial surfaces Pending CA3027969A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662350772P 2016-06-16 2016-06-16
US62/350,772 2016-06-16
PCT/US2017/037954 WO2017218942A1 (en) 2016-06-16 2017-06-16 Compositions and methods of treating dry syndrome and other traumatized non-keratinized epithelial surfaces

Publications (1)

Publication Number Publication Date
CA3027969A1 true CA3027969A1 (en) 2017-12-21

Family

ID=60663416

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3027969A Pending CA3027969A1 (en) 2016-06-16 2017-06-16 Compositions and methods of treating dry eye syndrome and other traumatized non-keratinized epithelial surfaces

Country Status (6)

Country Link
US (3) US11191781B2 (OSRAM)
EP (1) EP3471742A4 (OSRAM)
JP (3) JP7148987B2 (OSRAM)
CN (1) CN109862899A (OSRAM)
CA (1) CA3027969A1 (OSRAM)
WO (1) WO2017218942A1 (OSRAM)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109862899A (zh) 2016-06-16 2019-06-07 护眼国际有限责任公司 治疗干眼综合征及其他创伤性非角质化上皮表面的组合物和方法
WO2019231133A1 (ko) * 2018-05-31 2019-12-05 주식회사 엑소코바이오 줄기세포 유래의 엑소좀을 유효성분으로 포함하는 모공 축소용 조성물
WO2020113075A1 (en) * 2018-11-29 2020-06-04 Cellula Llc The composition of umbilical cord blood serum
EP3968965A1 (en) * 2019-05-13 2022-03-23 Bone Therapeutics S.A. Improved lyophilized formulations involving hyaluronic acid and plasmatic proteins, and uses thereof
IT201900010740A1 (it) * 2019-07-02 2021-01-02 Medacta Int Sa Biocompatible compositions comprising a biocompatible thickening polymer and a chitosan derivative
WO2024003424A1 (es) * 2022-06-28 2024-01-04 Compliance Consulting And Engineering Services, S.L. Sistema para el control del proceso de liofilización en un liofilizador con sistema de castillo de placas y método para la generación de un espacio de diseño
US20240226181A1 (en) * 2023-01-11 2024-07-11 Biostem Technologies, Inc. Human umbilical cord composition for treatment of peyronie's disease
CN117017945B (zh) * 2023-08-14 2026-02-06 珠海横琴澳叶健康科技有限公司 一种离子响应型蒙花苷纳米粒子及其制备方法和应用
WO2025165681A1 (en) * 2024-01-31 2025-08-07 Serorepair Llc Serum compositions with additive for ocular delivery in animals
CN118662706B (zh) * 2024-06-17 2025-01-10 韶关朗圣药业有限公司 一种人体润滑液及其制备方法和应用
EP4740931A1 (en) * 2024-11-06 2026-05-13 Oral Care Solutions GmbH Oral care composition for use in the treatment of dry mouth

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9713980D0 (en) 1997-07-03 1997-09-10 Danbiosyst Uk New conjugates
EP1128809B1 (en) * 1998-11-20 2004-12-29 Laboratoire Medidom S.A. Aqueous ophthalmic formulations comprising chitosan
WO2003094937A1 (en) 2002-05-09 2003-11-20 Medigenes A pharmaceutical composition for treatment of wounds containing blood plasma or serum
US20080299212A1 (en) * 2005-02-25 2008-12-04 Medigenes Co., Ltd Pharmaceutical Composition for Treating Avellino Cornea Dystrophy Comprising Blood Plasma or Serum
US20090035289A1 (en) * 2005-09-26 2009-02-05 Lifecell Corporation Dry platelet composition
WO2007059084A2 (en) * 2005-11-14 2007-05-24 The New England Medical Center Hospitals, Inc. Methods for preparing cord matrix stem cells (cmsc) for long term storage and for preparing a segment of umbilical cord for cryopreservation
US8932560B2 (en) 2007-09-04 2015-01-13 University of Maryland, College Parke Advanced functional biocompatible polymeric matrix used as a hemostatic agent and system for damaged tissues and cells
US20090223080A1 (en) * 2007-03-19 2009-09-10 Hemcon Medical Technologies, Inc. Apparatus and methods for making, storing, and administering freeze-dried materials such as freeze-dried plasma
US7776022B2 (en) 2007-03-19 2010-08-17 Hemcon Medical Technologies Apparatus and methods for making, storing, and administering freeze-dried materials such as freeze-dried plasma
WO2010085792A1 (en) * 2009-01-26 2010-07-29 Oregon Biomedical Engineering Institute Dehydrated plasma kit
CN101829048B (zh) * 2010-01-21 2012-04-18 厦门大学 一种滴眼液及其制备方法
ES2368394B1 (es) * 2011-07-13 2012-06-08 Banc De Sang I Teixits Composición que comprende plasma de sangre de cordon umbilical para el tratamiento de patologías de la superficie ocular y procedimiento de obtención de la misma.
WO2014028745A2 (en) 2012-08-17 2014-02-20 Archon Pharmaceutical Consulting Llc A system for compounding and packaging ready to reconstitute drug powders of solutions to a solution or to a suspension or to an injectable
CA2914610C (en) 2013-03-13 2022-08-02 University Of Maryland Advanced functional biocompatible polymer putty used as a hemostatic agent for treating damaged tissue and cells
EP3052083A4 (en) 2013-09-30 2017-05-03 Bioactive Regenerative Therapeutics, Inc. Biomimetic hybrid gel compositions and methods of use
AU2015221389B2 (en) 2014-02-20 2018-12-13 Ortho Regenerative Technologies Inc. Freeze-dried polymer compositions for mixing with platelet rich plasma to form implants for tissue repair and/or compositions for therapeutic intra-articular injections
EP3119392A4 (en) * 2014-03-17 2017-10-11 Encompass Development Inc. Ocular formulations
CA2963435A1 (en) * 2014-10-06 2016-04-14 Fondazione Irccs Ca' Granda - Ospedale Maggiore Policlinico Umbilical cord blood plasma for treatment of corneal pathology
DE102015205293A1 (de) * 2015-03-24 2016-09-29 Marc Schrott Verfahren zur Herstellung von Augentropfen
CN109862899A (zh) 2016-06-16 2019-06-07 护眼国际有限责任公司 治疗干眼综合征及其他创伤性非角质化上皮表面的组合物和方法

Also Published As

Publication number Publication date
WO2017218942A1 (en) 2017-12-21
JP7473237B2 (ja) 2024-04-23
WO2017218942A8 (en) 2019-01-24
EP3471742A1 (en) 2019-04-24
US11191781B2 (en) 2021-12-07
JP2019525951A (ja) 2019-09-12
US11534459B2 (en) 2022-12-27
US20230321145A1 (en) 2023-10-12
US20220168341A1 (en) 2022-06-02
CN109862899A (zh) 2019-06-07
EP3471742A4 (en) 2020-03-04
JP2024096781A (ja) 2024-07-17
US20190175647A1 (en) 2019-06-13
JP7148987B2 (ja) 2022-10-06
JP2022191232A (ja) 2022-12-27

Similar Documents

Publication Publication Date Title
US11534459B2 (en) Compositions and methods of treating dry eye syndrome and other traumatized non-keratinized epithelial surfaces
Vigani et al. Recent advances in the development of in situ gelling drug delivery systems for non-parenteral administration routes
Nguyen et al. Advancing the stimuli response of polymer-based drug delivery systems for ocular disease treatment
Majeed et al. Ocular in situ gel: An overview.
BRPI0708622A2 (pt) terapia ocular usando agentes que ativam a sirtuina
Goyal et al. Current nanotechnological strategies for treating glaucoma
Mundada et al. In situ gelling polymers in ocular drug delivery systems: a review
JP2014510724A (ja) 熱応答性ハイドロゲル組成物
Das et al. The gamut of perspectives, challenges, and recent trends for in situ hydrogels: A smart ophthalmic drug delivery vehicle
Wang et al. Applications and recent developments of hydrogels in ophthalmology
Calles et al. Polymers in ophthalmology
Osi et al. Pharmaceutical, biomedical and ophthalmic applications of biodegradable polymers (BDPs): literature and patent review
CN101810563B (zh) 他克莫司眼用在体凝胶制剂及其制备方法
Rostamipoor et al. Topical ocular administration using thermosensitive chitosan-glycerophosphate-PRP hydrogels for improved ocular bioavailability
Wang et al. Imatinib@ glycymicelles entrapped in hydrogel: preparation, characterization, and therapeutic effect on corneal alkali burn in mice
EP3570815B1 (en) Composition for ophthalmic use
CN118902984A (zh) 序贯控释双药物负载可注射水凝胶及其制备方法和应用
CN105214071A (zh) 一种纤连蛋白类滴眼液及其制备方法
ES2796361T3 (es) Uso terapéutico de una solución oftálmica acuosa estéril
CN104721130B (zh) 一种布林佐胺包合物眼用制剂及其制备方法
Singh et al. Novel Approach and Recent Advancement In-Situ Gel as Smart Carriers for Controlled Drug Delivery via Ophthalmic Route
HK40009946A (en) Compositions and methods of treating dry eye syndrome and other traumatized non-keratinized epithelial surfaces
RU2232582C2 (ru) Глазная пленка
Bhanu Malhotra et al. Ocular drug delivery systems.
EP3804773A1 (en) Viscoelastic agent material

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220520

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250205

R00 Party data change recorded

Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R00-R113 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CHANGE OF ADDRESS OR METHOD OF CORRESPONDENCE REQUEST RECEIVED

Effective date: 20250206

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 8TH ANNIV.) - STANDARD

Year of fee payment: 8

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250522

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250522

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250523

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250526

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20251217

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20251217

R18 Changes to party contact information recorded

Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R18-R114 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CHANGE OF METHOD OF CORRESPONDENCE REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260423

Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R18-R143 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CHANGE OF ADDRESS REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260423

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260423

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 9TH ANNIV.) - STANDARD

Year of fee payment: 9

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260428

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260428